RxDoctor Payments Data

Erika Orban

Adult Health · Seattle, WANPI 1578071916

Payments from drug & device makers

What this record shows

Convatec Inc. accounts for 77.5% of it on its own, with 7 other manufacturers making up the rest. Among adult health clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,796in general payments, 2019–2025

Across 22 payments — averaging $127.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Convatec Inc.$2K
  • Solventum Corporation$282
  • Hollister Incorporated$140
  • Johnson & Johnson$69
  • Antares Pharma, Inc.$50
  • Astellas Pharma US Inc$38
  • plus $50 from 2 others

What the payments were for

  • Travel & lodging$1,43051%
  • Food & beverage$1,36649%

General payments by program year

22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,796 in reported general payments places this provider in the 90th percentile of 252 adult health providers in Washington.

See all adult health providers in Washington

Medicare billing

Part B allowed, 2024
$5,354
Medicare patients
46
Services billed
74

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron12$12,725
RenacidinCitric Ac/Gluconolact/Mag Carb13$4,127
Oxybutynin Chloride ErOxybutynin Chloride38$595
Tamsulosin Hcl47$398
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst25$245
Finasteride23$150
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$27

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$38$12,72512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 252 adult health providers in Washington.

Other adult health in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →